Literature DB >> 12154085

Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes.

Jeremy Wechsler1, Young-Hun Choi, Judith Krall, Faiyaz Ahmad, Vincent C Manganiello, Matthew A Movsesian.   

Abstract

PDE3A cyclic nucleotide phosphodiesterases regulate cAMP- and cGMP-mediated intracellular signaling in cardiac myocytes. We used antibodies to different regions of PDE3A to demonstrate the presence of three PDE3A isoforms in these cells. These isoforms, whose apparent molecular weights are 136,000, 118,000, and 94,000 ("PDE3A-136," "PDE3A-118," and "PDE3A-94"), are identical save for the deletion of different lengths of N-terminal sequence containing two membrane-association domains and sites for phosphorylation/activation by protein kinase B ("PK-B") and protein kinase A ("PK-A"). PDE3A-136 contains both membrane-association domains and the PK-B and PK-A sites. PDE3A-118 contains only the downstream membrane-association domain and the PK-A sites. PDE3A-94 lacks both membrane localization domains and the PK-B and PK-A sites. The three isoforms are translated from two mRNAs derived from the PDE3A1 gene: PDE3A-136 is translated from PDE3A1 mRNA, whereas PDE3A-118 and PDE3A-94 are translated from PDE3A2 mRNA. Experiments involving in vitro transcription/translation indicate that PDE3A-118 and PDE3A-94 may be translated from different AUGs in PDE3A2 mRNA. These findings suggest that alternative transcriptional and post-transcriptional processing of the PDE3A gene results in the generation of two mRNAs and three protein isoforms in cardiac myocytes that differ with respect to intracellular localization and may be regulated through different signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154085     DOI: 10.1074/jbc.M203647200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.

Authors:  Youn Wook Chung; Claudia Lagranha; Yong Chen; Junhui Sun; Guang Tong; Steven C Hockman; Faiyaz Ahmad; Shervin G Esfahani; Dahae H Bae; Nazari Polidovitch; Jian Wu; Dong Keun Rhee; Beom Seob Lee; Marjan Gucek; Mathew P Daniels; Christine A Brantner; Peter H Backx; Elizabeth Murphy; Vincent C Manganiello
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-15       Impact factor: 11.205

3.  A positive feedback loop contributes to the deleterious effects of angiotensin.

Authors:  Laurence L Brunton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

4.  Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells.

Authors:  C J Busch; A R Graveline; K Jiramongkolchai; H Liu; L S Sanchez; K D Bloch
Journal:  J Physiol Pharmacol       Date:  2010-12       Impact factor: 3.011

Review 5.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

6.  Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.

Authors:  Xiaoyun Wu; Gavin R Schnitzler; Galen F Gao; Brett Diamond; Andrew R Baker; Bethany Kaplan; Kaylyn Williamson; Lindsay Westlake; Selena Lorrey; Timothy A Lewis; Colin W Garvie; Martin Lange; Sikander Hayat; Henrik Seidel; John Doench; Andrew D Cherniack; Charlotte Kopitz; Matthew Meyerson; Heidi Greulich
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

7.  cUMP hydrolysis by PDE3A.

Authors:  Stefan Berrisch; Jessica Ostermeyer; Volkhard Kaever; Solveig Kälble; Denise Hilfiker-Kleiner; Roland Seifert; Erich H Schneider
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-14       Impact factor: 3.000

8.  Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility.

Authors:  Silvia Masciarelli; Kathleen Horner; Chengyu Liu; Sun Hee Park; Mary Hinckley; Steven Hockman; Taku Nedachi; Catherine Jin; Marco Conti; Vincent Manganiello
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Identification, characterization and subcellular localization of TcPDE1, a novel cAMP-specific phosphodiesterase from Trypanosoma cruzi.

Authors:  Maximiliano A D'Angelo; Santiago Sanguineti; Jeffrey M Reece; Lutz Birnbaumer; Héctor N Torres; Mirtha M Flawiá
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

Review 10.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.